BACKGROUND: Long-lasting effects of withdrawal from nicotine are hypothesized to contribute to relapse and persistence of tobacco habits, and significant evidence supports a role of monoamine oxidase inhibitors (MAOI) contained in cigarette smoke as potent modulators of the rewarding effects of tobacco. METHODS: With quantification of somatic signs of withdrawal and the place aversion conditioning paradigm, we assessed the effects of MAOI pretreatment on both somatic and aversive motivational components of mecamylamine-induced nicotine withdrawal in rats rendered dependent on nicotine by the subcutaneous implantation of osmotic minipumps (vehicle or nicotine tartrate 9 mg/kg/day). RESULTS: In nicotine-infused rats, mecamylamine induced a place aversion that lasted 6 weeks. When nicotine-infused rats were also treated with a MAOI, mecamylamine-induced conditioned place aversion persisted for at least 8 months of abstinence. The MAOI treatment slightly decreased ratings of somatic signs induced by mecamylamine administration but had no effect on the threshold or the magnitude of mecamylamine-induced conditioned place aversion. CONCLUSIONS: These results show that MAOI pretreatment induces a long-lasting conditioned placed aversion associated with nicotine withdrawal, possibly through a potentiation of learning and memory process, and provides some indications on protracted abstinence that might be useful for delineating the neurobiological substrate of relapse.
BACKGROUND: Long-lasting effects of withdrawal from nicotine are hypothesized to contribute to relapse and persistence of tobacco habits, and significant evidence supports a role of monoamine oxidase inhibitors (MAOI) contained in cigarette smoke as potent modulators of the rewarding effects of tobacco. METHODS: With quantification of somatic signs of withdrawal and the place aversion conditioning paradigm, we assessed the effects of MAOI pretreatment on both somatic and aversive motivational components of mecamylamine-induced nicotine withdrawal in rats rendered dependent on nicotine by the subcutaneous implantation of osmotic minipumps (vehicle or nicotine tartrate 9 mg/kg/day). RESULTS: In nicotine-infused rats, mecamylamine induced a place aversion that lasted 6 weeks. When nicotine-infused rats were also treated with a MAOI, mecamylamine-induced conditioned place aversion persisted for at least 8 months of abstinence. The MAOI treatment slightly decreased ratings of somatic signs induced by mecamylamine administration but had no effect on the threshold or the magnitude of mecamylamine-induced conditioned place aversion. CONCLUSIONS: These results show that MAOI pretreatment induces a long-lasting conditioned placed aversion associated with nicotine withdrawal, possibly through a potentiation of learning and memory process, and provides some indications on protracted abstinence that might be useful for delineating the neurobiological substrate of relapse.
Authors: Shahrdad Lotfipour; Monica M Arnold; Derk J Hogenkamp; Kelvin W Gee; James D Belluzzi; Frances M Leslie Journal: Neuropharmacology Date: 2011-03-23 Impact factor: 5.250
Authors: Ivan Berlin; Ian M Hunneyball; Doris Greiling; Stephen P Jones; Hermann Fuder; Hans-Detlev Stahl Journal: Psychopharmacology (Berl) Date: 2012-03-27 Impact factor: 4.530
Authors: Andrea H Weinberger; Erin L Reutenauer; Peter I Jatlow; Stephanie S O'Malley; Marc N Potenza; Tony P George Journal: Drug Alcohol Depend Date: 2009-11-24 Impact factor: 4.492
Authors: Selina Baeza-Loya; Humsini Viswanath; Asasia Carter; David L Molfese; Kenia M Velasquez; Philip R Baldwin; Daisy G Y Thompson-Lake; Carla Sharp; J Christopher Fowler; Richard De La Garza; Ramiro Salas Journal: Bull Menninger Clin Date: 2014